References
- FerkolTSchraufnagelDThe global burden of respiratory diseaseAnn Am Thorac Soc201411340440624673696
- National Heart, Lung and Blood InstituteMorbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases2012 Available from: http://www.nhlbi.nih.gov/research/reports/2012-mortality-chart-bookAccessed 22 July, 2015
- RiesALImpact of chronic obstructive pulmonary disease on quality of life: the role of dyspneaAm J Med200611910 Suppl 1122016996895
- Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease2016 Available from: http://www.goldcopd.orgAccessed February 2, 2016
- Seebri Breezhaler® (glycopyrronium bromide) [summary of product characteristics]Nuremberg, GermanyNovartis Pharma GmbH2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdfAccessed February 2, 2016
- DomingoCUltra-LAMA, ultra-LABA, ultra-inhaled steroids? The future has landedArch Bronconeumol201349413113423415574
- D’UrzoAKerwinEOverendTD’AndreaPChenHGoyalPOnce daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studiesCurr Med Res Opin201430349350824156566
- ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
- KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
- ArievichHOverendTRenardDA novel model-based approach for dose determination of glycopyrronium bromide in COPDBMC Pulm Med2012127423217058
- FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease10292015 Available from: http://www.pharma.us.novartis.com/info/newsroom/news-description.jsp?id=137236Accessed May 2, 2016
- JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
- WangCSunTHuangYEfficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 studyInt J Chron Obstruct Pulmon Dis201510576825609940
- KesslerRPartridgeMRMiravitllesMSymptom variability in patients with severe COPD: a pan-European cross-sectional studyEur Respir J201137226427221115606
- RocheNChavannesNHMiravitllesMCOPD symptoms in the morning: impact, evaluation and managementRespir Res20131411224143997
- BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
- DecramerMCooperCBTreatment of COPD: the sooner the better?Thorax201065983784120805184
- RennardSIScanlonPDFergusonGTACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Investig20133312893904